<?xml version="1.0" encoding="UTF-8"?>
<fn-group>
 <fn id="fn1-1040710">
  <p>Check the online version for the most updated information on this article, online supplements, and information on authorship &amp; disclosures: 
   <ext-link ext-link-type="uri" xlink:href="www.haematologica.org/content/104/4/710" xmlns:xlink="http://www.w3.org/1999/xlink">www.haematologica.org/content/104/4/710</ext-link>
  </p>
 </fn>
 <fn id="fn2-1040710">
  <p>
   <bold>Funding</bold>
  </p>
  <p>This investigator-initiated trial was supported by grants from the Rising Tide Foundation, Gateway for Cancer Research, Swiss Cancer League (KFS-3655-02-2015), and the Swiss National Science Foundation (KFS-3539-08-2014) (31003A_166613) to RCS, ERC-2014-CoG-648765 grant to SMF, and the Swiss Cancer League to JRP. The SAKK organization is supported by the Swiss State Secretary for Education, Research and Innovation, Swiss Cancer Research Foundation and the Swiss Cancer League. The study drug mirabegron was provided free of charge by Astellas Pharma AG Switzerland.</p>
 </fn>
</fn-group>
